Novo Nordisk A/S buy matumba
Summary
This prediction ended on 12.08.13 with a price of €25.91. With a performance of 6.58%, the BUY prediction by matumba for Novo Nordisk A/S closed with a slight gain. matumba has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
Comments by matumba for this prediction
In the thread Novo Nordisk A/S diskutieren
Idealer Einstieg
Jetzt erst recht.
auch wenn nicht heute der US Markt läuft, so tut er es morgen.
immerhin sind die Dänen die Nummer eins im Insulin - Bereich .
zUschlagen